# T1D Gene Therapy Platform - Custom License Agreement

**Version 1.0**  
**Effective Date: 27th June 2025**  
**Copyright Â© 2025 Abdullah M. Doumi. All Rights Reserved.**

---

## PREAMBLE

This Custom License Agreement (the "License") governs the use of the collection of intellectual property assets, including but not limited to scientific papers, technical protocols, conceptual designs, and all associated materials (collectively, "the Work"), related to the T1D Gene Therapy Platform conceived and authored by Abdullah M. Doumi ("the Author").

This Work is made publicly available to foster academic discourse, accelerate scientific innovation, and invite strategic partnerships for its commercial development. This License is designed to clearly delineate the permissions granted for Non-Commercial Use while explicitly reserving all rights related to Commercial Use. By accessing, viewing, or otherwise using the Work, you ("the User") agree to be bound by the terms of this License.

---

## ARTICLE 1: DEFINITIONS

1.1. **"The Work"** refers to all materials contained within this repository and all derivative intellectual property, including the scientific concepts, methodologies, protocols, written text, diagrams, and strategic analyses authored by Abdullah M. Doumi.

1.2. **"Non-Commercial Use"** is defined as any use for purposes of personal education, academic research at a non-profit institution, teaching, scientific critique, or peer review. Any research funded in whole or in part by a for-profit entity does not qualify as Non-Commercial Use.

1.3. **"Commercial Use"** is defined as any use of the Work, in whole or in part, for any purpose that is primarily intended for or directed toward commercial advantage, monetary compensation, or in connection with a for-profit entity. This includes, but is not limited to:
    (a) Incorporation into any product, service, or process that is sold, licensed, or otherwise monetized.
    (b) Use as a basis for filing patent applications or securing any other form of intellectual property protection.
    (c) Use in contract research, internal R&D, or evaluation by or for a for-profit corporation.
    (d) Use to provide paid consulting or advisory services.

1.4. **"Commercial License"** refers to a separate, written agreement executed between the User and the Author that grants specific rights for Commercial Use in exchange for negotiated consideration (e.g., fees, royalties).

---

## ARTICLE 2: GRANT OF NON-COMMERCIAL LICENSE

2.1. **Permissions Granted.** Subject to the terms and conditions of this License, the Author hereby grants the User a worldwide, non-exclusive, royalty-free, non-sublicensable, non-transferable, limited license to engage in Non-Commercial Use of the Work.

2.2. **Attribution Requirement.** For any Non-Commercial Use, including academic publications, presentations, or public discussions, the User must provide clear and prominent attribution to the Author as follows:
    > "Conceptual framework based on the T1D Gene Therapy Platform by Abdullah M. Doumi. [Link to the original GitHub repository]."

---

## ARTICLE 3: PROHIBITION OF COMMERCIAL USE

3.1. **Strict Prohibition.** All rights not expressly granted for Non-Commercial Use are reserved by the Author. **Any and all Commercial Use of the Work is strictly prohibited** without first obtaining a separate Commercial License from the Author.

3.2. **No Implied License.** No provision of this License shall be construed as granting, by implication, estoppel, or otherwise, any license for Commercial Use. The availability of the Work for public viewing does not constitute a waiver of the Author's commercial rights.

---

## ARTICLE 4: INTELLECTUAL PROPERTY

4.1. **Ownership.** The Author retains sole and exclusive ownership of all rights, title, and interest in and to the Work, including all copyrights and the right to seek patent protection in any jurisdiction worldwide.

4.2. **Improvements and Derivatives.** Any new inventions, discoveries, or improvements made by the User based on or derived from the Confidential Information or the Work shall be promptly disclosed to the Author. The terms of ownership and licensing for such new inventions will be subject to separate negotiation. This clause is intended to prevent the User from circumventing this License by creating a minimally modified version of the Work.

---

## ARTICLE 5: OBTAINING A COMMERCIAL LICENSE

5.1. **Inquiry.** Parties interested in pursuing Commercial Use of the Work must contact the Author directly to initiate licensing discussions.

5.2. **Negotiation.** The terms of any Commercial License are subject to negotiation and will be tailored to the specific use case. Such terms may include, but are not limited to, upfront fees, milestone payments, royalties, and/or equity.

**Contact for Commercial Licensing:**
Abdullah M. Doumi
Email: `abdullah.crispr.project1@outlook.com`

---

## ARTICLE 6: DISCLAIMER OF WARRANTY & LIMITATION OF LIABILITY

6.1. **"AS IS" BASIS.** THE WORK IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF SCIENTIFIC VALIDITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT. THE ENTIRE RISK AS TO THE QUALITY, ACCURACY, AND PERFORMANCE OF THE WORK IS WITH THE USER.

6.2. **LIMITATION OF LIABILITY.** IN NO EVENT SHALL THE AUTHOR BE LIABLE FOR ANY CLAIM, DAMAGES, OR OTHER LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT, OR OTHERWISE, ARISING FROM, OUT OF, OR IN CONNECTION WITH THE WORK OR THE USE OR OTHER DEALINGS IN THE WORK.

---
